Ryan Takahashi

Characterization of Differential Tissue Abundance of Major Non-CYP Enzymes in Human

Abdul Basit, Naveen K. Neradugomma, Christopher C. Wolford et al. · Molecular Pharmaceutics · 2020 · 82 citations

Pathology, Redox Biology, Toxicological Mechanism +23

Overcoming Preclinical Safety Obstacles to Discover (<i>S</i>)-<i>N</i>-((1,2,3,5,6,7-Hexahydro-<i>s</i>-indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro-5<i>H</i>-pyrazolo[5,1-<i>b</i>][1,3]oxazine-3-sulfonamide (GDC-2394): A Potent and Selective NLRP3 Inhibitor

Christopher McBride, Lynnie Trzoss, Davide Povero et al. · Journal of Medicinal Chemistry · 2022 · 65 citations · Full text

Characterization of the Ontogeny of Hepatic UDP‐Glucuronosyltransferase Enzymes Based on Glucuronidation Activity Measured in Human Liver Microsomes

Justine Badée, NaHong Qiu, Abby C. Collier et al. · The Journal of Clinical Pharmacology · 2019 · 64 citations

Structure-Based Design of Tricyclic NF-κB Inducing Kinase (NIK) Inhibitors That Have High Selectivity over Phosphoinositide-3-kinase (PI3K)

Georgette M. Castanedo, Nicole Blaquière, Maureen H. Beresini et al. · Journal of Medicinal Chemistry · 2016 · 58 citations · Full text

Drug Target, Pharmacotherapy, Chemical Biology +18

Absorption, Metabolism, Excretion, and the Contribution of Intestinal Metabolism to the Oral Disposition of [14C]Cobimetinib, a MEK Inhibitor, in Humans

Ryan Takahashi, Edna F. Choo, S. Wong et al. · Drug Metabolism and Disposition · 2015 · 44 citations